Madrigal Pharmaceuticals insider trading
MDGLfinancial statementsForm 4 filings on EDGAR473 transactions since Nov 1, 2024
From August 4, 2026 to November 1, 2026, 0 insiders at Madrigal Pharmaceuticals bought $0 of stock in the open market, and 2 sold $7M. Officers and directors accounted for $0 of purchases and $7M of sales. The last reported transaction was an open-market sale by Sibold William John on September 11, 2026.
The answer card and chart use the same period. Change the range above the chart to update both. Form 4 filings through September 11, 2026; awards, option exercises, tax withholding and gifts are excluded from these totals.
Stock price and insider activity
Daily price candles with insider purchases and sales directly beneath them on the same timeline. Bars show individual days; totals sum all days in the selected period.
Bought $0Sold $7MAug 4, 2026 – Nov 1, 2026
purchases above zero; sales below. Both use the transaction date and the same dollar scale. Hover, tap, or use arrow keys to inspect a date. Awards, exercises, tax withholding and gifts are excluded.
Dates with prices or insider activity are spaced evenly; empty weekends and holidays are omitted. Prices through Oct 30, 2026. Insider data through Nov 1, 2026. Prices are adjusted for splits; transaction values are reported dollars.
Every transaction
473 transactions from November 1, 2024 to November 1, 2026, newest first. Open-market purchases and sales are coloured; awards, exercises, tax withholding and gifts are grey and not counted.
| Traded | Insider | Role | Transaction | Shares | Price | Value | Held after | Filed |
|---|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | Sibold William John | President and CEO, Director | open-market sale10b5-1 | 60 | $533.09 | $32K | 202,907 | Sep 11, 2026 |
| Sep 11, 2026 | Sibold William John | President and CEO, Director | open-market sale10b5-1 | 106 | $534.06 | $57K | 202,801 | Sep 11, 2026 |
| Sep 11, 2026 | Sibold William John | President and CEO, Director | open-market sale10b5-1 | 218 | $535.94 | $117K | 202,583 | Sep 11, 2026 |
| Sep 11, 2026 | Sibold William John | President and CEO, Director | open-market sale10b5-1 | 160 | $537.62 | $86K | 202,423 | Sep 11, 2026 |
| Sep 11, 2026 | Sibold William John | President and CEO, Director | open-market sale10b5-1 | 687 | $540.59 | $371K | 201,736 | Sep 11, 2026 |
| Sep 11, 2026 | Sibold William John | President and CEO, Director | open-market sale10b5-1 | 368 | $541.64 | $199K | 201,368 | Sep 11, 2026 |
| Sep 11, 2026 | Sibold William John | President and CEO, Director | open-market sale10b5-1 | 1,202 | $542.60 | $652K | 200,166 | Sep 11, 2026 |
| Sep 11, 2026 | Sibold William John | President and CEO, Director | open-market sale10b5-1 | 1,539 | $544.02 | $837K | 198,627 | Sep 11, 2026 |
| Sep 11, 2026 | Sibold William John | President and CEO, Director | open-market sale10b5-1 | 761 | $544.83 | $415K | 197,866 | Sep 11, 2026 |
| Sep 11, 2026 | Sibold William John | President and CEO, Director | open-market sale10b5-1 | 120 | $546.38 | $66K | 197,746 | Sep 11, 2026 |
| Sep 9, 2026 | Sibold William John | President and CEO, Director | open-market sale10b5-1 | 131 | $527.88 | $69K | 209,198 | Sep 11, 2026 |
| Sep 9, 2026 | Sibold William John | President and CEO, Director | open-market sale10b5-1 | 347 | $529.27 | $184K | 208,851 | Sep 11, 2026 |
| Sep 9, 2026 | Sibold William John | President and CEO, Director | open-market sale10b5-1 | 522 | $530.23 | $277K | 208,329 | Sep 11, 2026 |
| Sep 9, 2026 | Sibold William John | President and CEO, Director | open-market sale10b5-1 | 368 | $531.99 | $196K | 207,961 | Sep 11, 2026 |
| Sep 9, 2026 | Sibold William John | President and CEO, Director | open-market sale10b5-1 | 512 | $533.09 | $273K | 207,449 | Sep 11, 2026 |
| Sep 9, 2026 | Sibold William John | President and CEO, Director | open-market sale10b5-1 | 396 | $534.20 | $212K | 207,053 | Sep 11, 2026 |
| Sep 9, 2026 | Sibold William John | President and CEO, Director | open-market sale10b5-1 | 644 | $535.27 | $345K | 206,409 | Sep 11, 2026 |
| Sep 9, 2026 | Sibold William John | President and CEO, Director | open-market sale10b5-1 | 1,040 | $536.11 | $558K | 205,369 | Sep 11, 2026 |
| Sep 9, 2026 | Sibold William John | President and CEO, Director | open-market sale10b5-1 | 640 | $537.17 | $344K | 204,729 | Sep 11, 2026 |
| Sep 9, 2026 | Sibold William John | President and CEO, Director | open-market sale10b5-1 | 520 | $538.30 | $280K | 204,209 | Sep 11, 2026 |
| Sep 9, 2026 | Sibold William John | President and CEO, Director | open-market sale10b5-1 | 215 | $539.03 | $116K | 203,994 | Sep 11, 2026 |
| Sep 9, 2026 | Sibold William John | President and CEO, Director | open-market sale10b5-1 | 505 | $540.19 | $273K | 203,489 | Sep 11, 2026 |
| Sep 9, 2026 | Sibold William John | President and CEO, Director | open-market sale10b5-1 | 362 | $541.65 | $196K | 203,127 | Sep 11, 2026 |
| Sep 9, 2026 | Sibold William John | President and CEO, Director | open-market sale10b5-1 | 160 | $542.55 | $87K | 202,967 | Sep 11, 2026 |
| Aug 17, 2026 | Kelley Shannon T | General Counsel | open-market sale | 664 | $514.97 | $342K | 11,474 | Aug 20, 2026 |
| Aug 15, 2026 | Reed John C | Director | award | 647 | $0.00 | — | 647 | Aug 18, 2026 |
| Jul 20, 2026 | Sibold William John | President and CEO, Director | open-market sale | 140 | $542.75 | $76K | 211,689 | Jul 20, 2026 |
| Jul 20, 2026 | Sibold William John | President and CEO, Director | open-market sale | 110 | $543.79 | $60K | 211,579 | Jul 20, 2026 |
| Jul 20, 2026 | Sibold William John | President and CEO, Director | open-market sale | 545 | $544.71 | $297K | 211,034 | Jul 20, 2026 |
| Jul 20, 2026 | Sibold William John | President and CEO, Director | open-market sale | 275 | $545.71 | $150K | 210,759 | Jul 20, 2026 |
| Jul 20, 2026 | Sibold William John | President and CEO, Director | open-market sale | 269 | $547.08 | $147K | 210,490 | Jul 20, 2026 |
| Jul 20, 2026 | Sibold William John | President and CEO, Director | open-market sale | 680 | $547.70 | $372K | 209,810 | Jul 20, 2026 |
| Jul 20, 2026 | Sibold William John | President and CEO, Director | open-market sale | 47 | $548.87 | $26K | 209,763 | Jul 20, 2026 |
| Jul 20, 2026 | Sibold William John | President and CEO, Director | open-market sale | 153 | $550.01 | $84K | 209,610 | Jul 20, 2026 |
| Jul 20, 2026 | Sibold William John | President and CEO, Director | open-market sale | 1 | $550.72 | $551 | 209,609 | Jul 20, 2026 |
| Jul 20, 2026 | Sibold William John | President and CEO, Director | open-market sale | 280 | $555.05 | $155K | 209,329 | Jul 20, 2026 |
| Jul 17, 2026 | Sibold William John | President and CEO, Director | option exercise | 50,000 | — | — | 211,829 | Jul 20, 2026 |
| Jun 17, 2026 | Taub Rebecca | Director | award | 454 | $0.00 | — | 452,667 | Jun 18, 2026 |
| Jun 17, 2026 | Levy Richard S | Director | award | 454 | $0.00 | — | 22,469 | Jun 18, 2026 |
| Jun 17, 2026 | Fouse Jacqualyn A | Director | award | 454 | $0.00 | — | 1,551 | Jun 18, 2026 |
| Jun 17, 2026 | Daly James M | Director | award | 454 | $0.00 | — | 3,081 | Jun 18, 2026 |
| Jun 17, 2026 | Brennan Daniel J. | Director | award | 404 | $0.00 | — | 1,371 | Jun 18, 2026 |
| Jun 17, 2026 | Baker BROS. Advisors LP+5 more | Director | awardindirect | 908 | $0.00 | — | 203,721 | Jun 18, 2026 |
| Jun 17, 2026 | Baker BROS. Advisors LP+5 more | Director | awardindirect | 908 | $0.00 | — | 2M | Jun 18, 2026 |
| Jun 1, 2026 | Soergel David | Chief Medical Officer | open-market sale10b5-1 | 1,042 | $495.74 | $517K | 10,033 | Jun 1, 2026 |
| May 22, 2026 | Levy Richard S | Director | open-market sale10b5-1 | 40 | $506.68 | $20K | 27,657 | May 22, 2026 |
| May 22, 2026 | Levy Richard S | Director | open-market sale10b5-1 | 320 | $508.24 | $163K | 27,337 | May 22, 2026 |
| May 22, 2026 | Levy Richard S | Director | open-market sale10b5-1 | 151 | $510.36 | $77K | 27,186 | May 22, 2026 |
| May 22, 2026 | Levy Richard S | Director | open-market sale10b5-1 | 610 | $511.40 | $312K | 26,576 | May 22, 2026 |
| May 22, 2026 | Levy Richard S | Director | open-market sale10b5-1 | 439 | $512.50 | $225K | 26,137 | May 22, 2026 |
Who the insiders are
Everyone who reported a transaction since November 1, 2024, by open-market value over twelve months. Shares held are after the insider’s latest directly held transaction.
| Insider | Role | Last transaction | Kind | Shares held | Bought, 12 months | Sold, 12 months | Sales under a plan |
|---|---|---|---|---|---|---|---|
| Friedman Paul A | Director | Jan 9, 2026 | option exercise | 187,444 | — | $27M (38) | 38 of 38 |
| Taub Rebecca | Pres., R&D, and CMO, Director | Jun 17, 2026 | award | 452,667 | — | $22M (42) | 39 of 42 |
| Sibold William John | President and CEO, Director | Sep 11, 2026 | open-market sale | 202,907 | — | $10M (37) | 24 of 37 |
| Bate Kenneth | Director | Nov 5, 2025 | option exercise | 18,097 | — | $8M (11) | 0 of 11 |
| Levy Richard S | Director | Jun 17, 2026 | award | 22,469 | — | $7M (26) | 26 of 26 |
| Dier Mardi | EVP and CFO | Mar 6, 2026 | open-market sale | 12,690 | — | $4M (28) | 27 of 28 |
| Huntsman Carole | Chief Commercial Officer | Mar 6, 2026 | open-market sale | 12,692 | — | $2M (14) | 13 of 14 |
| Soergel David | Chief Medical Officer | Jun 1, 2026 | open-market sale | 10,033 | — | $952K (2) | 1 of 2 |
| Kelley Shannon T | General Counsel | Aug 17, 2026 | open-market sale | 11,474 | — | $842K (4) | 2 of 4 |
| Baker Felix | Director | Aug 18, 2025 | open-market buy | — | — | — | — |
| Baker Bros. Advisors (GP) LLC | Director | Aug 20, 2025 | open-market buy | — | — | — | — |
| Craves Fred B | Director | Mar 13, 2025 | open-market sale | 350,076 | — | — | — |
| Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Mar 5, 2025 | award | 5,789 | — | — | — |
| Daly James M | Director | Jun 17, 2026 | award | 3,081 | — | — | — |
| Fouse Jacqualyn A | Director | Jun 17, 2026 | award | 1,551 | — | — | — |
| Brennan Daniel J. | Director | Jun 17, 2026 | award | 1,371 | — | — | — |
| Baker BROS. Advisors LP | Director | Jun 17, 2026 | award | — | — | — | — |
| Reed John C | Director | Aug 15, 2026 | award | 647 | — | — | — |
| Thakkar Rita | Chief Accounting Officer | Jan 15, 2026 | award | 2,398 | — | — | — |
Questions
Are Madrigal Pharmaceuticals insiders buying or selling?
Over the twelve months to November 1, 2026, 9 insiders at Madrigal Pharmaceuticals sold $81M of stock in the open market, all by officers and directors, and no insider bought. Net, insiders sold $81M. Only open-market purchases and sales are counted.
Who sold the most Madrigal Pharmaceuticals stock in the last year?
Friedman Paul A (Director) sold $27M in 38 open-market sales over the twelve months to November 1, 2026.
Do Madrigal Pharmaceuticals executives sell under 10b5-1 plans?
170 of the 202 open-market sales in the last twelve months (84%) were reported as made under a Rule 10b5-1 trading plan, set up in advance. A sale under a plan is still counted as a sale.
What counts as insider buying here?
Only open-market purchases (Form 4 code P) and sales (code S) by officers, directors and 10% owners. Stock awards, option exercises, shares withheld for tax and gifts are listed in the table but never counted as buying or selling.
More on Madrigal Pharmaceuticals
- Madrigal Pharmaceuticals financial statements
- 2 tracked funds holding MDGL
- Insider buying and selling across all companies
- These transactions as JSON
From Form 4, 4/A and 5 filings with the SEC. A record of insider transactions, not a recommendation.